Pacific Shuanglin Bio pharmacy Co Ltd Total Assets
Pacific Shuanglin Bio pharmacy Co Ltd total assets. Based on the latest financial reports, Pacific Shuanglin Bio pharmacy Co Ltd (000403) holds total assets worth CN¥9.78 Billion CNY (≈ $1.43 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Pacific Shuanglin Bio pharmacy Co Ltd (000403) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Pacific Shuanglin Bio pharmacy Co Ltd (1993–2025)
Total assets of Pacific Shuanglin Bio pharmacy Co Ltd from 1993 to 2025. This chart illustrates how Pacific Shuanglin Bio pharmacy Co Ltd's total assets have evolved over time, based on quarterly financial data. See Pacific Shuanglin Bio pharmacy Co Ltd stock quote for real-time trading data and today's change.
Pacific Shuanglin Bio pharmacy Co Ltd - Asset Composition Analysis
Pacific Shuanglin Bio pharmacy Co Ltd Total Assets Breakdown (December 2025)
Pacific Shuanglin Bio pharmacy Co Ltd total assets breakdown as of December 2025. Pacific Shuanglin Bio pharmacy Co Ltd's total assets of CN¥9.78 Billion consist of 39.3% current assets and 60.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.1% |
| Accounts Receivable | CN¥929.58 Million | 9.8% |
| Inventory | CN¥1.56 Billion | 16.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥368.28 Million | 3.9% |
| Goodwill | CN¥2.54 Billion | 26.8% |
Asset Composition Trend (1993–2025)
This chart illustrates how Pacific Shuanglin Bio pharmacy Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Pacific Shuanglin Bio pharmacy Co Ltd (000403) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pacific Shuanglin Bio pharmacy Co Ltd's current assets represent 39.3% of total assets in 2025, a decrease from 76.7% in 1993.
- Cash Position: Cash and equivalents constituted 8.1% of total assets in 2025, up from 2.4% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, an increase from 0.0% in 1993.
- Asset Diversification: The largest asset category is goodwill at 26.8% of total assets.
Pacific Shuanglin Bio pharmacy Co Ltd Competitors by Total Assets
Key competitors of Pacific Shuanglin Bio pharmacy Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Pacific Shuanglin Bio pharmacy Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.04 | 3.67 | 4.46 |
| Quick Ratio | 1.56 | 1.90 | 2.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.63 Billion | CN¥2.42 Billion | CN¥1.77 Billion |
Pacific Shuanglin Bio pharmacy Co Ltd - Advanced Valuation Insights
This section examines the relationship between Pacific Shuanglin Bio pharmacy Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.22 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | 2.4% |
| Total Assets | CN¥9.47 Billion |
| Market Capitalization | $1.37 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Pacific Shuanglin Bio pharmacy Co Ltd's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Pacific Shuanglin Bio pharmacy Co Ltd's assets grew by 2.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Pacific Shuanglin Bio pharmacy Co Ltd (1993–2025)
The table below shows the annual total assets of Pacific Shuanglin Bio pharmacy Co Ltd from 1993 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥9.47 Billion ≈ $1.39 Billion |
+2.38% |
| 2024-12-31 | CN¥9.25 Billion ≈ $1.35 Billion |
+7.14% |
| 2023-12-31 | CN¥8.63 Billion ≈ $1.26 Billion |
+8.12% |
| 2022-12-31 | CN¥7.98 Billion ≈ $1.17 Billion |
+12.62% |
| 2021-12-31 | CN¥7.09 Billion ≈ $1.04 Billion |
+328.88% |
| 2020-12-31 | CN¥1.65 Billion ≈ $241.83 Million |
+29.96% |
| 2019-12-31 | CN¥1.27 Billion ≈ $186.08 Million |
-3.48% |
| 2018-12-31 | CN¥1.32 Billion ≈ $192.80 Million |
-0.23% |
| 2017-12-31 | CN¥1.32 Billion ≈ $193.24 Million |
+6.21% |
| 2016-12-31 | CN¥1.24 Billion ≈ $181.94 Million |
-1.74% |
| 2015-12-31 | CN¥1.27 Billion ≈ $185.15 Million |
+5.99% |
| 2014-12-31 | CN¥1.19 Billion ≈ $174.69 Million |
+0.56% |
| 2013-12-31 | CN¥1.19 Billion ≈ $173.72 Million |
+11.16% |
| 2012-12-31 | CN¥1.07 Billion ≈ $156.27 Million |
+11.15% |
| 2011-12-31 | CN¥960.80 Million ≈ $140.60 Million |
+3.82% |
| 2010-12-31 | CN¥925.41 Million ≈ $135.42 Million |
-26.07% |
| 2009-12-31 | CN¥1.25 Billion ≈ $183.18 Million |
+3.05% |
| 2008-12-31 | CN¥1.21 Billion ≈ $177.76 Million |
-26.80% |
| 2007-12-31 | CN¥1.66 Billion ≈ $242.84 Million |
-2.70% |
| 2006-12-31 | CN¥1.71 Billion ≈ $249.56 Million |
-18.11% |
| 2005-12-31 | CN¥2.08 Billion ≈ $304.74 Million |
-1.56% |
| 2004-12-31 | CN¥2.12 Billion ≈ $309.58 Million |
-5.60% |
| 2003-12-31 | CN¥2.24 Billion ≈ $327.93 Million |
+45.09% |
| 2002-12-31 | CN¥1.54 Billion ≈ $226.02 Million |
+12.03% |
| 2001-12-31 | CN¥1.38 Billion ≈ $201.74 Million |
+16.98% |
| 2000-12-31 | CN¥1.18 Billion ≈ $172.46 Million |
+22.67% |
| 1999-12-31 | CN¥960.75 Million ≈ $140.59 Million |
+83.38% |
| 1998-12-31 | CN¥523.91 Million ≈ $76.66 Million |
+31.86% |
| 1997-12-31 | CN¥397.33 Million ≈ $58.14 Million |
+20.13% |
| 1996-12-31 | CN¥330.76 Million ≈ $48.40 Million |
+65.85% |
| 1995-12-31 | CN¥199.43 Million ≈ $29.18 Million |
+4.11% |
| 1994-12-31 | CN¥191.55 Million ≈ $28.03 Million |
+0.31% |
| 1993-12-31 | CN¥190.95 Million ≈ $27.94 Million |
-- |
About Pacific Shuanglin Bio pharmacy Co Ltd
Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of blood products in China and internationally. The company offers human serum albumin, human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, human coagulation factor VIII, human fibrinogen… Read more